Check the appropriate box:

(Name of Registrant as Specified In Its Charter)

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Two Peer Review Articles Published in the June 2011 Edition of Obstetrics & Gynecology that Discuss the Performance of OVA1^® - Two peer-reviewed manuscripts highlighting OVA1’s sensitivity for ovarian cancer were published in the June issue of Obstetrics and Gynecology, which is published by the American College of Gynecologists and Oncologists (ACOG). The first manuscript, “Performance of the American College of Obstetricians and Gynecologists’ Ovarian Tumor Referral Guidelines With a Multivariate Index Assay” demonstrated that OVA1 would improve detection of cancer if incorporated into standard of care recommended by ACOG. The second manuscript, “Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors” demonstrated that OVA1 would improve detection of cancer if incorporated into physician evaluation of women with ovarian masses. The publication of these manuscripts is an important milestone in our commercialization efforts for OVA1. First, they will be used as sales aids by our market development team to support medical education and marketing programs. Second, while we have made great progress in increasing coverage for OVA1, manuscripts such as these are often required by major payers as part of the process of coverage decision-making. We expect these two publications to have a significant impact on our test sales.

Continued Progress in Expanding our Intellectual Property Portfolio - We have received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent entitled “Saposin D and Fam3C are Biomarkers for Alzheimer’s Disease.” Our expanding patent portfolio, not just for peripheral artery disease but also for our other diagnostic programs, plays a key role in creating stockholder value and protecting our diagnostic assets.

Leading Proxy Advisory Firms Endorse Vermillion Board Nominees - ISS Proxy Advisory Services (ISS), Glass Lewis & Co. LLC and Egan-Jones Proxy Services, the three leading and independent proxy advisory firms that advise institutional investors on proxy voting, have published recommendations that stockholders vote FOR all board nominees up for election, FOR the advisory vote on the compensation of our Named Executive Officers and FOR the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2011. Additionally, ISS and Glass Lewis have recommended an annual advisory vote on executive compensation and Egan-Jones has recommended a triennial advisory vote on executive compensation.